MCID: CNT005
MIFTS: 56

Central Nervous System Lymphoma

Categories: Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases, Blood diseases

Aliases & Classifications for Central Nervous System Lymphoma

MalaCards integrated aliases for Central Nervous System Lymphoma:

Name: Central Nervous System Lymphoma 12 15
Primary Central Nervous System Lymphoma 73
Primary Cns Lymphoma 12
Cns Lymphoma 73
Microglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3234
ICD9CM 35 200.5
NCIt 50 C9301

Summaries for Central Nervous System Lymphoma

Disease Ontology : 12 A hematologic cancer that has material basis in lymphoma located in central nervous system.

MalaCards based summary : Central Nervous System Lymphoma, also known as primary central nervous system lymphoma, is related to primary central nervous system lymphoma and intraocular lymphoma. An important gene associated with Central Nervous System Lymphoma is MYD88 (Myeloid Differentiation Primary Response 88), and among its related pathways/superpathways are NF-KappaB Family Pathway and Folate Metabolism. The drugs Methotrexate and Cytarabine have been mentioned in the context of this disorder. Affiliated tissues include central nervous system, brain and b cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Central Nervous System Lymphoma

Diseases in the Central Nervous System Lymphoma family:

Primary Central Nervous System Lymphoma

Diseases related to Central Nervous System Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 161)
# Related Disease Score Top Affiliating Genes
1 primary central nervous system lymphoma 33.9 BCL6 CDKN2A CXCL12 MGMT MYD88
2 intraocular lymphoma 32.8 BCL6 CXCL12 IL10
3 acquired immunodeficiency syndrome 30.7 BCL6 IL10 IL2
4 testicular lymphoma 30.2 BCL6 FOXP1 MYD88
5 glioma 29.5 CDKN2A IL2 MIR184 TP53
6 leukemia, chronic lymphocytic 29.5 BCL6 CXCL12 IL2 TP53
7 lymphoma, non-hodgkin, familial 28.5 BCL6 CXCL12 IL2 MALT1 TP53
8 diffuse large b-cell lymphoma 28.1 BCL6 FOXP1 MALT1 MYD88 PRDM1 TP53
9 b-cell lymphomas 28.0 BCL6 CDKN2A FOXP1 MALT1 PRDM1 TP53
10 lymphoma 11.2
11 neurological complications of aids 11.0
12 primary cutaneous diffuse large b-cell lymphoma, leg type 10.8 CDKN2A MYD88
13 anaplastic oligodendroglioma 10.7 CDKN2A MGMT
14 colon lymphoma 10.7 BCL6 CDKN2A
15 retinitis pigmentosa 22 10.7 CDKN2A IL10
16 brain stem astrocytic neoplasm 10.7 CDKN2A TP53
17 keratinizing squamous cell carcinoma 10.6 CDKN2A TP53
18 spitz nevus 10.6 CDKN2A TP53
19 bladder carcinoma in situ 10.6 CDKN2A TP53
20 balanoposthitis 10.6 CDKN2A IL2
21 primary mediastinal large b-cell lymphoma 10.6 BCL6 FOXP1
22 bartholin's gland benign neoplasm 10.6 CDKN2A TP53
23 vulva squamous cell carcinoma 10.6 CDKN2A TP53
24 thyroid lymphoma 10.6 CDKN2A TP53
25 nasal cavity adenocarcinoma 10.6 CDKN2A TP53
26 bone squamous cell carcinoma 10.6 CDKN2A TP53
27 scrotal carcinoma 10.5 CDKN2A TP53
28 glycogen-rich clear cell breast carcinoma 10.5 CDKN2A TP53
29 breast giant fibroadenoma 10.5 CDKN2A MGMT
30 gastric adenosquamous carcinoma 10.5 CDKN2A TP53
31 clonorchiasis 10.5 IL10 IL2
32 oral leukoplakia 10.5 CDKN2A TP53
33 fibrillary astrocytoma 10.5 MGMT TP53
34 anogenital venereal wart 10.5 CDKN2A TP53
35 megaesophagus 10.5 CDKN2A TP53
36 cervix uteri carcinoma in situ 10.5 CDKN2A TP53
37 cervicitis 10.5 CDKN2A IL2
38 lymphoplasmacytic lymphoma 10.5 CXCL12 MYD88
39 schneiderian carcinoma 10.4 CDKN2A TP53
40 nodal marginal zone b-cell lymphoma 10.4 BCL6 MALT1
41 human immunodeficiency virus infectious disease 10.4 CXCL12 IL10 IL2
42 meningeal melanomatosis 10.4 CDKN2A TP53
43 anal squamous cell carcinoma 10.4 CDKN2A MGMT TP53
44 dedifferentiated liposarcoma 10.4 CDKN2A TP53
45 grade iii astrocytoma 10.3 CDKN2A MGMT TP53
46 immune deficiency disease 10.3 CXCL12 IL10 IL2
47 plasmablastic lymphoma 10.3 BCL6 CDKN2A PRDM1
48 melanoma, cutaneous malignant 1 10.3 CDKN2A MGMT TP53
49 suppressor of tumorigenicity 3 10.3 CDKN2A TP53
50 oligodendroglioma 10.3 CDKN2A MGMT TP53

Graphical network of the top 20 diseases related to Central Nervous System Lymphoma:



Diseases related to Central Nervous System Lymphoma

Symptoms & Phenotypes for Central Nervous System Lymphoma

GenomeRNAi Phenotypes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

26 (show all 21)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10 PRDM1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-12 10 PRDM1 TP53 MGMT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10 PRDM1 TP53
4 Increased shRNA abundance (Z-score > 2) GR00366-A-132 10 TP53
5 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10 PRDM1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10 PRDM1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10 TP53
8 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10 PRDM1 TP53
9 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10 TP53
10 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10 MGMT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10 PRDM1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10 TP53
13 Increased shRNA abundance (Z-score > 2) GR00366-A-37 10 MGMT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10 TP53
15 Increased shRNA abundance (Z-score > 2) GR00366-A-5 10 MGMT
16 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10 PRDM1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-92 10 MGMT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10 PRDM1
19 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 MYD88 CDKN2A IL10 TP53 IL2 MALT1
20 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 MYD88 CDKN2A IL10 TP53 IL2 MALT1
21 Decreased TP53 mRNA expression GR00389-S-5 9.16 PRDM1 TP53

MGI Mouse Phenotypes related to Central Nervous System Lymphoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.11 TP53 MYD88 PRDM1 MALT1 CXCL12 BCL6
2 mortality/aging MP:0010768 10.11 TP53 MTR MYD88 PRDM1 CXCL12 MGMT
3 cardiovascular system MP:0005385 10.1 TP53 MYD88 PRDM1 CXCL12 BCL6 IL10
4 immune system MP:0005387 10.09 TP53 MYD88 PRDM1 MALT1 CXCL12 BCL6
5 endocrine/exocrine gland MP:0005379 10.08 TP53 MGMT MYD88 PRDM1 BCL6 IL10
6 liver/biliary system MP:0005370 9.95 TP53 PRDM1 BCL6 IL10 CDKN2A IL2
7 no phenotypic analysis MP:0003012 9.81 MYD88 PRDM1 TP53 MGMT BCL6 IL10
8 muscle MP:0005369 9.8 TP53 PRDM1 CXCL12 BCL6 IL10 CDKN2A
9 neoplasm MP:0002006 9.8 TP53 MYD88 PRDM1 MGMT IL10 CDKN2A
10 reproductive system MP:0005389 9.56 TP53 MYD88 PRDM1 CXCL12 BCL6 IL10
11 respiratory system MP:0005388 9.17 TP53 MGMT MYD88 BCL6 IL10 CDKN2A

Drugs & Therapeutics for Central Nervous System Lymphoma

Drugs for Central Nervous System Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 261)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
2
Cytarabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
4
Teniposide Approved Phase 4 29767-20-2 34698
5
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
6
leucovorin Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
7
Fotemustine Experimental, Investigational Phase 4
8 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
19 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
21 Folate Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
22 Vitamin B9 Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
23
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
24
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
25
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
26
Ofloxacin Approved Phase 3 82419-36-1 4583
27
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
28
rituximab Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
29
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 85622-93-1 5394
30
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
31
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
32
Thiotepa Approved, Investigational Phase 3,Phase 2 52-24-4 5453
33
Dalteparin Approved Phase 3 9005-49-6
34
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
35
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
36
Ondansetron Approved Phase 3,Not Applicable 99614-02-5 4595
37
Amphotericin B Approved, Investigational Phase 3,Phase 1,Phase 2 1397-89-3 14956 5280965
38
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
39
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
40
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
41
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
42
Idarubicin Approved Phase 2, Phase 3,Phase 3 58957-92-9 42890
43
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 68538-85-2
44
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
45
Carmustine Approved, Investigational Phase 3,Phase 2 154-93-8 2578
46
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
47
Mechlorethamine Approved, Investigational Phase 3,Phase 1,Phase 2 51-75-2 4033
48
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
49 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
50 Analgesics Phase 3,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 171)
# Name Status NCT ID Phase Drugs
1 Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) Completed NCT00153530 Phase 4 methotrexate
2 Treatment of Primary CNS Lymphoma Recruiting NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
5 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
6 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
8 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
9 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
10 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
11 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
12 Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL Recruiting NCT02836158 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
13 Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma Recruiting NCT02313389 Phase 3 Rituximab, Methotrexate, Temozolomide
14 High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma Recruiting NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
15 Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy Enrolling by invitation NCT02657785 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
16 a Phase II Study in Primary Central Nervous System Lymphoma Unknown status NCT00455286 Phase 2 Methotrexate;Methylprednisolone;Temozolomide
17 Chemotherapy and Radiation Therapy in Treating Patients With HIV-Related Primary Central Nervous System Lymphoma Unknown status NCT00003261 Phase 2 methotrexate;zidovudine
18 Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma Unknown status NCT00942747 Phase 2 temsirolimus
19 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2 methotrexate;thiotepa
20 Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma (PCNSL) Unknown status NCT01985451 Phase 2 Pemetrexe;Temozolomide
21 Methotrexate and Temozolomide Versus Methotrexate, Procarbazine, Vincristine and Cytarabine Unknown status NCT00503594 Phase 2 Methotrexate and temozolomide;Methotrexate , procarbazine ,vincristine ,cytarabine
22 Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma Unknown status NCT01735747 Phase 2 nedaplatin;vincristine;Temozolomide
23 Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma Unknown status NCT00989352 Phase 2 Methotrexate;Lomustine;Procarbazine;Rituximab
24 High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement Unknown status NCT00801216 Phase 2 High-dose sequential chemotherapy and autologous transplant
25 Combination Chemotherapy Plus Filgrastim in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma Unknown status NCT00032149 Phase 1, Phase 2 cyclophosphamide;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
26 Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer Unknown status NCT00387530 Phase 2 oral sodium phenylbutyrate;valganciclovir
27 PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Completed NCT02669511 Phase 2 PQR309
28 Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma Completed NCT00193973 Phase 2 Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
29 Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma Completed NCT01011920 Phase 2 Methotrexate;Ara-C;Rituximab;Thiotepa;BCNU
30 Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00006264 Phase 2 ganciclovir;zidovudine
31 Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Completed NCT02301364 Phase 2 Buparlisib (BKM120)
32 Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma Completed NCT00210314 Phase 2 high dose methotrexate;high dose cytarabine
33 Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074191 Phase 2 cytarabine;dexamethasone;lomustine;methotrexate;procarbazine hydrochloride
34 Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma Completed NCT00074178 Phase 2 cyclophosphamide;cytarabine;dexamethasone;etoposide phosphate;methotrexate
35 Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Completed NCT00068250 Phase 1, Phase 2 rituximab;methotrexate;temozolomide 100 mg/m^2;temozolomide 150 mg/m^2;temozolomide 200 mg/m^2;post-radiation therapy temozolomide
36 Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00000801 Phase 2 Filgrastim;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Cytarabine;Dexamethasone
37 High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study Completed NCT01083342 Phase 2 MTX, MVD, VIA
38 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Central Nervous System Lymphoma Completed NCT00003632 Phase 2 carmustine;cytarabine;etoposide;melphalan;methotrexate
39 Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS Completed NCT00002940 Phase 2 hydroxyurea
40 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Primary CNS Lymphoma Completed NCT00003061 Phase 2 cytarabine;methotrexate
41 Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT00098774 Phase 2 cytarabine;etoposide;leucovorin calcium;methotrexate;temozolomide
42 Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT00045539 Phase 2 leucovorin calcium;methotrexate;thiotepa
43 High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma Completed NCT01182415 Phase 2 High-dose chemotherapy
44 Methotrexate, Glucarpidase, and Leucovorin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Completed NCT00727831 Phase 1, Phase 2 glucarpidase;leucovorin calcium;methotrexate
45 Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma Completed NCT00248534 Phase 2 methylprednisolone;temozolomide
46 Interferon Alfa in Treating Children With HIV-Related Cancer Completed NCT00002621 Phase 2
47 A Study for Patients With Non-Hodgkin's Lymphomas Completed NCT00542919 Phase 2 enzastaurin
48 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
49 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2
50 Topotecan Hydrochloride in Treating Children With Meningeal Cancer That Has Not Responded to Previous Treatment Completed NCT00005811 Phase 2 topotecan hydrochloride

Search NIH Clinical Center for Central Nervous System Lymphoma

Genetic Tests for Central Nervous System Lymphoma

Anatomical Context for Central Nervous System Lymphoma

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Lymphoma:

19
Central Nervous System

MalaCards organs/tissues related to Central Nervous System Lymphoma:

41
Brain, B Cells, Liver, Bone, Breast, Bone Marrow, Kidney

Publications for Central Nervous System Lymphoma

Articles related to Central Nervous System Lymphoma:

(show top 50) (show all 725)
# Title Authors Year
1
Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994-2013). ( 29796994 )
2018
2
Primary central nervous system lymphoma at the cerebellopontine angle mimicking a trigeminal schwannoma: A unique case report and literature review. ( 29656000 )
2018
3
Primary Central Nervous System Lymphoma-PART 1: Epidemiology, Diagnosis, Staging, and Prognosis. ( 29447417 )
2018
4
Significance of treatment response when managing patients with primary central nervous system lymphoma. ( 29966463 )
2018
5
Apparent diffusion coefficient value for a B-cell central nervous system lymphoma in a cat. ( 29383265 )
2018
6
Discrepancy Between Low Levels of mTOR Activity and High Levels of P-S6 in Primary Central Nervous System Lymphoma May Be Explained by PAS Domain-Containing Serine/Threonine-Protein Kinase-Mediated Phosphorylation. ( 29361117 )
2018
7
Primary central nervous system lymphoma in a patient with systemic lupus erythematosus mimicking high-grade glioma: A case report and review of literature. ( 29879076 )
2018
8
Intraventricular treatment of secondary central nervous system lymphoma - Case study and literature overview. ( 29703403 )
2018
9
Machine Learning-based Texture Analysis of Contrast-enhanced MR Imaging to Differentiate between Glioblastoma and Primary Central Nervous System Lymphoma. ( 29769456 )
2018
10
MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis. ( 29258950 )
2018
11
Challenges and prospects in the diagnosis and treatment of primary central nervous system lymphoma. ( 29633883 )
2018
12
Intraoperative Flow Cytometry Enables the Differentiation of Primary Central Nervous System Lymphoma from Glioblastoma. ( 29330078 )
2018
13
Stereotactic brachytherapy with iodine-125 seeds plus temozolomide induce complete and durable remission in a patient with recurrent primary central nervous system lymphoma. ( 29960094 )
2018
14
Population Pharmacokinetics of High-Dose Methotrexate in Patients With Primary Central Nervous System Lymphoma. ( 29331383 )
2018
15
Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation. ( 29438500 )
2018
16
B cell-rich non-neoplastic sentinel lesion preceding primary central nervous system lymphoma. ( 29871654 )
2018
17
Spinal primary central nervous system lymphoma: Case report and literature review. ( 29429785 )
2018
18
Is deep brain involvement in intracranial primary central nervous system lymphoma of importance for penetration of chemotherapeutic agents? ( 29804159 )
2018
19
Primary central nervous system lymphoma presenting as growing intracerebral hemorrhage. ( 29803066 )
2018
20
Isolated acute vestibular syndrome due to presumed primary central nervous system lymphoma involving the dorsal medulla. ( 29936666 )
2018
21
Craniotomy and Survival for Primary Central Nervous System Lymphoma. ( 29660011 )
2018
22
Treatment of newly diagnosed primary central nervous system lymphoma: current and emerging therapies. ( 29741421 )
2018
23
Leakage correction improves prognosis prediction of dynamic susceptibility contrast perfusion MRI in primary central nervous system lymphoma. ( 29323247 )
2018
24
Identification of novel recurrent ETV6-IGH fusions in primary central nervous system lymphoma. ( 29432597 )
2018
25
Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. ( 29679773 )
2018
26
Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05). ( 29416652 )
2018
27
Successful rapid drug desensitization to methotrexate in a patient with primary central nervous system lymphoma. ( 29662865 )
2018
28
<sup>18</sup>F-FDG PET/CT in immunocompetent patients with primary central nervous system lymphoma: Differentiation from glioblastoma and correlation with DWI. ( 29857862 )
2018
29
A rare case of paediatric primary central nervous system lymphoma treated with high-dose methotrexate and rituximab-based chemoimmunotherapy and whole brain radiotherapy followed by tumour bed boost with three-dimensional conformal radiation technique. ( 29744624 )
2018
30
A case of primary central nervous system lymphoma arising at the site of remote herpes encephalitis. ( 29382621 )
2018
31
Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities. ( 29891112 )
2018
32
Central nervous system lymphoma mimicking Bell palsy. ( 29883310 )
2018
33
Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma. ( 29937999 )
2018
34
Prognostic Significance of Interim 11C-Methionine PET/CT in Primary Central Nervous System Lymphoma. ( 29877882 )
2018
35
Presence of apoptosis distinguishes primary central nervous system lymphoma from glioblastoma during intraoperative consultation. ( 29336777 )
2018
36
Radiotherapy as an alternative treatment option for primary central nervous system lymphoma patients who are noncandidates for chemotherapy. ( 29290994 )
2017
37
Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study. ( 28982883 )
2017
38
Comparison between Glioblastoma and Primary Central Nervous System Lymphoma Using MR Image-based Texture Analysis. ( 28638001 )
2017
39
Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing. ( 28084866 )
2017
40
Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients. ( 28805292 )
2017
41
Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma. ( 28521029 )
2017
42
Proteomic changes in cerebrospinal fluid from primary central nervous system lymphoma patients are associated with protein ectodomain shedding. ( 29299134 )
2017
43
Quantitative Evaluation of Diffusion and Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Differentiation Between Primary Central Nervous System Lymphoma and Glioblastoma. ( 28806317 )
2017
44
Genome-wide DNA methylation profiling identifies primary central nervous system lymphoma as a distinct entity different from systemic diffuse large B-cell lymphoma. ( 28058506 )
2017
45
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. ( 27713090 )
2017
46
Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience. ( 28633037 )
2017
47
Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese. ( 29213063 )
2017
48
Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma. ( 28881844 )
2017
49
Relapsed or refractory primary central nervous system lymphoma radiosurgery: Report of the International Gamma Knife Research Foundation. ( 29296450 )
2017
50
High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for pediatric primary central nervous system lymphoma in first complete remission. ( 28542721 )
2017

Variations for Central Nervous System Lymphoma

Cosmic variations for Central Nervous System Lymphoma:

9
(show all 34)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10656 TP53 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.742C>T p.R248W 17:7674221-7674221 5
2 COSM43448 TNFAIP3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.2273C>G p.P758R 6:137881219-137881219 5
3 COSM5878666 TET2 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.4034A>C p.Y1345S 4:105261838-105261838 5
4 COSM4440697 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1255T>A p.S419T 3:177033132-177033132 5
5 COSM4440707 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.596G>A p.S199N 3:177050103-177050103 5
6 COSM4440703 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1376G>A p.S459N 3:177033011-177033011 5
7 COSM4440696 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1256C>T p.S419F 3:177033131-177033131 5
8 COSM4440698 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1335G>T p.V445V 3:177033052-177033052 5
9 COSM4440709 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.148A>T p.I50F 3:177053829-177053829 5
10 COSM4440712 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.230C>T p.P77L 3:177051701-177051701 5
11 COSM4440706 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.637C>A p.H213N 3:177050062-177050062 5
12 COSM4440705 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1274G>T p.R425M 3:177033113-177033113 5
13 COSM4440713 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.229C>A p.P77T 3:177051702-177051702 5
14 COSM4440710 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.70T>C p.S24P 3:177053907-177053907 5
15 COSM4440704 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1336T>G p.Y446D 3:177033051-177033051 5
16 COSM4440708 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.458G>A p.G153E 3:177050580-177050580 5
17 COSM4440695 TBL1XR1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1261G>C p.D421H 3:177033126-177033126 5
18 COSM1716590 STAT5B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1924A>C p.N642H 17:42207711-42207711 5
19 COSM1155745 STAT3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1981G>C p.D661H 17:42322402-42322402 5
20 COSM97163 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.556+1G>C p.? 6:106099553-106099553 5
21 COSM97162 PRDM1 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.183G>A p.E62fs 6:106088449-106088449 5
22 COSM85940 MYD88 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.794T>C p.L265P 3:38141150-38141150 5
23 COSM517 KRAS haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.34G>A p.G12S 12:25245351-25245351 5
24 COSM306058 JAK3 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1533G>T p.M511I 19:17838299-17838299 5
25 COSM5878665 DNMT3A haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.2207G>T p.R736L 2:25240417-25240417 5
26 COSM144393 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>A p.Y196N 17:63929439-63929439 5
27 COSM220733 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>C p.Y196S 17:63929438-63929438 5
28 COSM1737939 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>G p.Y196D 17:63929439-63929439 5
29 COSM220734 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.586T>C p.Y196H 17:63929439-63929439 5
30 COSM220736 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.587A>G p.Y196C 17:63929438-63929438 5
31 COSM5045028 CD79B haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.591G>C p.E197D 17:63929434-63929434 5
32 COSM43455 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>C p.F115L 7:2945834-2945834 5
33 COSM43452 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.343T>A p.F115I 7:2945834-2945834 5
34 COSM43451 CARD11 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.1010G>A p.R337Q 7:2938686-2938686 5

Expression for Central Nervous System Lymphoma

Search GEO for disease gene expression data for Central Nervous System Lymphoma.

Pathways for Central Nervous System Lymphoma

Pathways related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.44 CXCL12 IL2 MALT1 MYD88
2
Show member pathways
11.96 IL2 MTR TCN2 TP53
3 11.79 BCL6 PRDM1 TP53
4 11.71 BCL6 CDKN2A TP53
5 11.69 BCL6 IL10 TP53
6 11.68 CXCL12 IL10 IL2
7 11.68 BCL6 CXCL12 IL10 IL2 MALT1 MYD88
8 11.65 CDKN2A MGMT TP53
9 11.56 CXCL12 MALT1 MYD88
10
Show member pathways
11.49 IL10 IL2 MALT1 MYD88
11
Show member pathways
11.41 CDKN2A PRDM1 TP53
12 11.16 BCL6 IL10 PRDM1
13 11.04 CDKN2A IL2 TP53
14 10.98 IL10 IL2
15 10.89 CDKN2A TP53
16
Show member pathways
10.88 CDKN2A TP53
17 10.83 MTR TCN2

GO Terms for Central Nervous System Lymphoma

Cellular components related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 replication fork GO:0005657 8.62 BCL6 TP53

Biological processes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.88 BCL6 CDKN2A IL10 TP53
2 positive regulation of gene expression GO:0010628 9.85 CDKN2A MYD88 PRDM1 TP53
3 negative regulation of cell growth GO:0030308 9.71 BCL6 CDKN2A TP53
4 cytokine-mediated signaling pathway GO:0019221 9.65 BCL6 IL10 IL2 MYD88 TP53
5 regulation of inflammatory response GO:0050727 9.61 BCL6 FOXP1 MYD88
6 cobalamin metabolic process GO:0009235 9.57 MTR TCN2
7 negative regulation of cell-matrix adhesion GO:0001953 9.56 BCL6 CDKN2A
8 negative regulation of growth of symbiont in host GO:0044130 9.52 IL10 MYD88
9 response to molecule of bacterial origin GO:0002237 9.51 IL10 MALT1
10 replicative senescence GO:0090399 9.49 CDKN2A TP53
11 positive regulation of interleukin-17 production GO:0032740 9.48 IL2 MYD88
12 positive regulation of histone deacetylation GO:0031065 9.46 BCL6 TP53
13 positive regulation of regulatory T cell differentiation GO:0045591 9.4 BCL6 IL2
14 regulation of tumor necrosis factor production GO:0032680 9.37 FOXP1 MYD88
15 negative regulation of B cell proliferation GO:0030889 9.33 CDKN2A IL10 PRDM1
16 type 2 immune response GO:0042092 9.32 BCL6 IL10
17 negative regulation of apoptotic process GO:0043066 9.17 BCL6 IL10 IL2 MALT1 MGMT MYD88
18 negative regulation of B cell apoptotic process GO:0002903 9.13 BCL6 FOXP1 IL2

Molecular functions related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.43 CXCL12 IL10 IL2
2 cobalamin binding GO:0031419 9.16 MTR TCN2
3 kinase activator activity GO:0019209 8.96 IL2 MALT1
4 protein self-association GO:0043621 8.92 FOXP1 MALT1 MYD88 TP53

Sources for Central Nervous System Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....